Presenilin 1 (PSEN1) mutations are the main cause of autosomal dominant Early-onset Alzheimer Disease (EOAD). Among them, deletions of exon 9 have been reported to be associated with a phenotype of spastic paraparesis. Using exome data from a large sample of 522 EOAD cases and 584 controls to search for genomic copy-number variations (CNVs), we report here a novel partial, in-frame deletion of PSEN1, removing both exons 9 and 10. The patient presented with memory impairment associated with spastic paraparesis, both starting from the age of 56 years. He presented a positive family history of EOAD. We performed functional analysis to elucidate the impact of this novel deletion on PSEN1 activity as part of the γ-secretase complex. The deletion does not affect the assembly of a mature protease complex but has an extreme impact on its global endopeptidase activity. The mutant carboxypeptidase-like activity is also strongly impaired and the deleterious mutant effect leads to an incomplete digestion of long Aβ peptides and enhances the production of Aβ43, which has been shown to be potently amyloidogenic and neurotoxic in vivo.
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Introduction
Mutations in the Amyloid Precursor protein (APP), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) genes and duplications of the APP locus are the main causes of Autosomal Dominant Early-onset Alzheimer's disease (AD-EOAD). Mutations in the PSEN1 gene account for the majority of AD-EOAD cases with 221 pathogenic mutations reported to date (http://www.alzforum.org/), including 6 deletions of PSEN1 exon 9 resulting either from splicing mutations (Perez-Tur et al., 1995; Sato et al., 1998; Rovelet-Lecrux et al., 2015) or genomic deletions (Prihar et al., 1999; Hiltunen et al., 2000; Smith et al., 2001) .
Presenilin is the catalytic subunit of the γ-secretase, an enzymatic complex involved in the processing of numerous type 1 transmembrane proteins, including APP and Notch (Jurisch-Yaksi et al., 2013) . The sequential cleavage of APP by the β-and γ-secretase releases the Aβ peptides of different lengths. The accumulation of aggregation-prone Aβ peptides into senile plaques is central to AD pathophysiology. The γ-secretase cleavage occurs in a multi-step process: first, the endopeptidase (ε) cleavage releases the C-terminal part of APP (AICD) and, depending on the position of the ε-cleavage, either the Aβ49 or Aβ48 fragment will be produced. Then, carboxypeptidase-like γ-cleavages sequentially shorten these Aβ peptides following specific lines of production: Aβ49 → Aβ46 → Aβ43 → Aβ40 → Aβ37 and Aβ48 → Aβ45 → Aβ42 → Aβ38 (Takami et al., 2009) . AD-linked PSEN1 variations result in various effects on γ-secretase activity: whereas the endopeptidase cleavage is not always impaired, the carboxypeptidase efficiency is consistently reduced, resulting in qualitative shifts in Aβ profile, 
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